Dr. Paul Sax describes the reaction at the 2024 International AIDS Conference when results of the PURPOSE-1 study were presented, in
HIV and ID Observations.
If you're running a clinical trial, says Dr. Paul Sax, you dream about getting results like those from the PURPOSE-1 study of HIV prevention using twice-yearly injectable lenacapavir. There's a lot to commend about this clinical trial, the results of which were simultaneously published in the New England Journal of Medicine. Dr. Sax provides a partial list in the latest HIV and ID Observations.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.